Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Vertex Pharmaceuticals Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Vertex Pharmaceuticals Inc., consolidated cash flow statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income (loss)
Stock-based compensation expense
Depreciation and amortization expenses
Deferred income taxes
(Gains) losses on equity securities
Increase (decrease) in fair value of contingent consideration
Other non-cash items, net
Accounts receivable, net
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Other liabilities
Changes in operating assets and liabilities
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Net cash provided by (used in) operating activities
Purchases of available-for-sale debt securities
Sales and maturities of available-for-sale debt securities
Purchases of property and equipment
Sale of equity securities
Net payments related to finite-lived intangible assets
Acquisition of available-for-sale debt securities from Alpine Immune Sciences, Inc.
Payment to acquire ViaCyte, Inc., net of cash acquired
Other investing activities
Net cash (used in) provided by investing activities
Issuances of common stock under benefit plans
Repurchases of common stock
Payments in connection with common stock withheld for employee tax obligations
Payments on finance leases
Proceeds from finance leases
Other financing activities
Net cash used in financing activities
Effect of changes in exchange rates on cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Vertex Pharmaceuticals Inc. net cash provided by (used in) operating activities decreased from 2022 to 2023 and from 2023 to 2024.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Vertex Pharmaceuticals Inc. net cash (used in) provided by investing activities decreased from 2022 to 2023 and from 2023 to 2024.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Vertex Pharmaceuticals Inc. net cash used in financing activities decreased from 2022 to 2023 and from 2023 to 2024.